Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data
Matthieu Mahévas, Viet-Thi Tran, Mathilde Roumier, Amélie Chabrol, Romain Paule, Constance Guillaud, Elena Fois, Raphael Lepeule, Tali-Anne Szwebel, François-Xavier Lescure, Frédéric Schlemmer, Marie Matignon, Mehdi Khellaf, Etienne Crickx, Benjamin Terrier, Caroline Morbieu, Paul Legendre, Julien Dang, Yoland Schoindre, Jean-Michel Pawlotsky, Marc Michel, Elodie Perrodeau, Nicolas Carlier, Nicolas Roche, Victoire De Lastours, Clément Ourghanlian, Solen Kerneis, Philippe Ménager, Luc Mouthon, Etienne Audureau, Philippe Ravaud, Bertrand Godeau, Sébastien Gallien, Nathalie Costedoat-Chalumeau
BMJ, doi:10.1136/bmj.m1844
OBJECTIVE To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen.
DESIGN Comparative observational study using data collected from routine care.
SETTING Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March 2020. PARTICIPANTS 181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care.
CONCLUSIONS Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies. However, the results of this study do not support its use in patients admitted to hospital with covid-19 who require oxygen.
RESEARCH No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
References
Austin, Stuart, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies, Stat Med,
doi:10.1002/sim.6607Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, N Engl J Med,
doi:10.1056/NEJMoa2001282Chen, Hu, Zhang, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, Epidemiology,
doi:10.1101/2020.03.22.20040758Costedoat-Chalumeau, Dunogué, Morel, Guern, Guettrot-Imbert, Hydroxychloroquine: a multifaceted treatment in lupus, Presse Med,
doi:10.1016/j.lpm.2014.03.007Freund, Lemachatti, Krastinova, of Emergency Medicine Collaborators Group. Prognostic accuracy of sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department, Am J Epidemiol,
doi:10.1001/jama.2016.20329.on16Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Giudicessi, Noseworthy, Friedman, Ackerman, Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19), Mayo Clin,
doi:10.1016/j.mayocp.2020.03.024Hernán, Robins, Using big data to emulate a target trial when a randomized trial is not available, Am J Epidemiol,
doi:10.1093/aje/kwv254Kim, Sparks, Liew, Rheumatology Alliance †. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for covid-19, Ann Intern Med,
doi:10.7326/M20-1223Kuznik, Bencina, Svajger, Jeras, Rozman et al., Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines, J Immunol,
doi:10.4049/jimmunol.1000702Lenzer, Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence, BMJ,
doi:10.1136/bmj.m1335Lescure, Bouadma, Nguyen, Clinical and virological data of the first cases of COVID-19 in Europe: a case series, Lancet Infect Dis,
doi:10.1016/S1473-3099(20)30200-0Lunceford, Davidian, Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study [correction in, Stat Med
Molina, Delaugerre, Goff, No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe covid-19 infection, Med Mal Infect,
doi:10.1016/j.medmal.2020.03.006Patel, Verma, Covid-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?, JAMA,
doi:10.1001/jama.2020.4812Ranieri, Rubenfeld, Thompson, ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition, JAMA,
doi:10.1001/jama.2012.5669Singer, Deutschman, Seymour, The third international consensus definitions for sepsis and septic shock (Sepsis-3), JAMA,
doi:10.1001/jama.2016.0287Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA,
doi:10.1001/jama.2020.1585Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237Yazdany, Kim, Use of hydroxychloroquine and chloroquine during the covid-19 pandemic: what every clinician should know, Ann Intern Med,
doi:10.7326/M20-1334Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3
